N1-(2-氯苯基)-2-溴乙胺 | 5439-11-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N1-(2-氯苯基)-2-溴乙胺
• 中文别名: 2-溴-N-(2-氯苯基)乙酰胺
• 英文名称: 2-bromo-N-(2-chlorophenyl)acetamide
• CAS: 5439-11-2
• 化学式: C₈H₇BrClNO
• mdl: MFCD00173815
• 分子量: 248.507
• InChiKey: WIOJXHICOOQVAB-UHFFFAOYSA-N

物化性质

• 熔点：
  84-87°C
• 沸点：
  372.1±27.0 °C(Predicted)
• 密度：
  1.683±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26
• 危险类别码：
  R36/37/38
• 海关编码：
  2924299090

SDS

Name:	N1-(2-Chlorophenyl)-2-bromoacetamide 97% Material Safety Data Sheet
Synonym:	N-Bromoacetyl 2-chloroanilin
CAS:	5439-11-2

Section 1 - Chemical Product MSDS Name:N1-(2-Chlorophenyl)-2-bromoacetamide 97% Material Safety Data Sheet
Synonym:N-Bromoacetyl 2-chloroanilin

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
5439-11-2	N1-(2-Chlorophenyl)-2-bromoacetamide	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 5439-11-2: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 84 - 87 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H7BrClNO
Molecular Weight: 249

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, reducing agents, bases, amines.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, hydrogen cyanide, nitrogen oxides, carbon monoxide, carbon dioxide, hydrogen bromide, bromine.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 5439-11-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
N1-(2-Chlorophenyl)-2-bromoacetamide - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 5439-11-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 5439-11-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 5439-11-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N1-(2-氯苯基)-2-溴乙胺 在 sodium azide 、 水 作用下， 以 乙腈 为溶剂， 反应 12.0h， 生成 2-Azido-N-(2-chloro-phenyl)-acetamide
  参考文献：
  名称：

  新型 3-(1H-benzo[d]imidazol-2-yl)quinolin-2(1H)-one-based 三唑衍生物：作为抗增殖和凋亡诱导剂的设计、合成和生物学评价

  摘要：

  设计、合成了一系列基于喹啉-苯并咪唑杂化支架的 1,2,3-三唑衍生物，并针对一组 NCI-60 类人癌细胞系进行了体外细胞毒性评估，结果表明化合物Q6是最有效的细胞毒剂，对多种癌细胞系具有优异的 GI 50、TGI 和 LC 50值。Q6在 BT-474 乳腺癌线上进行了进一步测试，以评估作用机制。基于 3-(4,5-二甲基噻唑-2-基)-2,5-二苯基溴化四唑的初步筛选研究表明，化合物Q6对人乳腺癌细胞 BT-474 具有优异的抗增殖作用，IC 50值为 0.59 ± 0.01 μM。基于吖啶橙/溴化乙锭染色 (AO/EB) 和 4',6-二脒基-2-苯基吲哚 (DAPI) 测定的详细研究表明，显示的抗增殖活性是由于暴露于Q6时诱导细胞凋亡. 此外，DCFDA 染色显示活性氧的产生，改变了线粒体电位并导致细胞凋亡的开始。JC-1 染色进一步支持了这一点，表明该支架有助于开发更有效的衍生物。

  DOI：

  10.1002/ardp.202100074
• 作为产物：
  描述：

  溴乙酰溴 、 邻氯苯胺 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.25h， 以80%的产率得到N1-(2-氯苯基)-2-溴乙胺
  参考文献：
  名称：

  A synthesis, in silico, in vitro and in vivo study of thieno[2,3-b]pyridine anticancer analogues

  摘要：

  吡啶并噻吩[2,3-b]吡啶与TDP1结合，最佳类似物为9d，IC₅₀为0.5 μM。

  DOI：

  10.1039/c5md00245a

文献信息

• Synthesis and α-Glucosidase Inhibition Activity of 2-[3-(Benzoyl/4-bromobenzoyl)-4-hydroxy-1,1-dioxido-2H-benzo[e][1,2]thiazin-2-yl]-N-arylacetamides: An In Silico and Biochemical Approach
  作者：Furqan Ahmad Saddique、Sana Aslam、Matloob Ahmad、Usman Ali Ashfaq、Muhammad Muddassar、Sadia Sultan、Saman Taj、Muzammil Hussain、Dae Sung Lee、Magdi E. A. Zaki

  DOI：10.3390/molecules26103043

  日期：——

  Diabetes mellitus (DM) is a chronic disorder and has affected a large number of people worldwide. Insufficient insulin production causes an increase in blood glucose level that results in DM. To lower the blood glucose level, various drugs are employed that block the activity of the α-glucosidase enzyme, which is considered responsible for the breakdown of polysaccharides into monosaccharides leading to an increase in the intestinal blood glucose level. We have synthesized novel 2-(3-(benzoyl/4-bromobenzoyl)-4-hydroxy-1,1-dioxido-2H-benzo[e][1,2]thiazin-2-yl)-N-arylacetamides and have screened them for their in silico and in vitro α-glucosidase inhibition activity. The derivatives 11c, 12a, 12d, 12e, and 12g emerged as potent inhibitors of the α-glucosidase enzyme. These compounds exhibited good docking scores and excellent binding interactions with the selected residues (Asp203, Asp542, Asp327, His600, Arg526) during in silico screening. Similarly, these compounds also showed good in vitro α-glucosidase inhibitions with IC50 values of 30.65, 18.25, 20.76, 35.14, and 24.24 μM, respectively, which were better than the standard drug, acarbose (IC50 = 58.8 μM). Furthermore, a good agreement was observed between in silico and in vitro modes of study.

  糖尿病（DM）是一种慢性疾病，已经影响了全球大量人口。胰岛素产量不足导致血糖水平升高，从而引发糖尿病。为了降低血糖水平，使用了各种药物来阻断α-葡萄糖苷酶的活性，该酶被认为是将多糖分解为单糖，导致肠道血糖水平升高的原因。我们合成了新型的2-(3-(苯甲酰/对溴苯甲酰)-4-羟基-1,1-二氧化-2H-苯并[e][1,2]噻嗪-2-基)-N-芳基乙酰胺，并对它们进行了体外和体内α-葡萄糖苷酶抑制活性的筛选。衍生物11c、12a、12d、12e和12g显示出对α-葡萄糖苷酶的强效抑制作用。这些化合物在体外筛选过程中表现出良好的对接得分，并与所选残基（Asp203、Asp542、Asp327、His600、Arg526）展现出优秀的结合相互作用。同样，这些化合物在体内也表现出良好的α-葡萄糖苷酶抑制作用，其IC50值分别为30.65、18.25、20.76、35.14和24.24 μM，优于标准药物阿卡波糖（IC50 = 58.8 μM）。此外，在体内和体外研究模式之间观察到了良好的一致性。
• Cyclohexane derivatives and their use as therapeutic agents
  申请人：——

  公开号：US20030236250A1

  公开（公告）日：2003-12-25

  The present invention relates compounds of formula (I), wherein ring A is a phenyl or pyridyl ring; X represents a linker selected from the group consisting of formulae: (a), (b), (c), (d), and (e); and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 13 , R 14 , R 15 , R 16 , R 17 , R 21a and R 21b are as defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia. 1

  本发明涉及式(I)的化合物，其中环A是苯环或吡啶环；X代表从以下式组成的选择性连接物：(a)、(b)、(c)、(d)和(e)；以及R1、R2、R3、R4、R5、R6、R7、R13、R14、R15、R16、R17、R21a和R21b如本文所定义。这些化合物特别适用于治疗或预防抑郁症、焦虑、疼痛、炎症、偏头痛、呕吐或带状疱疹后神经痛。
• [EN] ION CHANNEL MODULATORS<br/>[FR] MODULATEURS DE CANAUX IONIQUES
  申请人：SCION PHARMACEUTICALS INC

  公开号：WO2005087750A1

  公开（公告）日：2005-09-22

  The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein cab be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel subtype targets.

  这项发明涉及化合物、包含这些化合物的组合物，以及使用这些化合物和化合物组合物的方法。这里描述的化合物、组合物和方法可用于治疗调节离子通道功能，以及治疗疾病和疾病症状，特别是那些由特定钙通道亚型靶点介导的疾病和疾病症状。
• Ion Channel Modulators
  申请人：Zelle Robert

  公开号：US20070281937A1

  公开（公告）日：2007-12-06

  The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel subtype targets.

  这项发明涉及化合物、包含这些化合物的组合物，以及使用这些化合物和化合物组合物的方法。本文描述的化合物、组合物和方法可用于治疗调节离子通道功能，以及治疗疾病和疾病症状，特别是那些由特定钙通道亚型靶点介导的疾病。
• Synthesis, in Vitro Evaluation and Cocrystal Structure of 4-Oxo-[1]benzopyrano[4,3-<i>c</i>]pyrazole <i>Cryptosporidium parvum</i> Inosine 5′-Monophosphate Dehydrogenase (<i>Cp</i>IMPDH) Inhibitors
  作者：Zhuming Sun、Jihan Khan、Magdalena Makowska-Grzyska、Minjia Zhang、Joon Hyung Cho、Chalada Suebsuwong、Pascal Vo、Deviprasad R. Gollapalli、Youngchang Kim、Andrzej Joachimiak、Lizbeth Hedstrom、Gregory D. Cuny

  DOI：10.1021/jm501527z

  日期：2014.12.26

  Cryptosporidium inosine 5′-monophosphate dehydrogenase (CpIMPDH) has emerged as a therapeutic target for treating Cryptosporidium parasites because it catalyzes a critical step in guanine nucleotide biosynthesis. A 4-oxo-[1]benzopyrano[4,3-c]pyrazole derivative was identified as a moderately potent (IC50 = 1.5 μM) inhibitor of CpIMPDH. We report a SAR study for this compound series resulting in 8k

  隐孢子虫肌苷5'-单磷酸脱氢酶（Cp IMPDH）已成为治疗隐孢子虫寄生虫的治疗靶标，因为它催化了鸟嘌呤核苷酸生物合成的关键步骤。一种4-氧代-[1]苯并吡喃并[4,3- c ]吡唑衍生物被确定为Cp IMPDH的中效抑制剂（IC 50 = 1.5μM）。我们报告了此化合物系列的SAR研究，结果为8k（IC 50 = 20±4 nM）。另外，还提出了Cp IMPDH·IMP· 8k的X射线晶体结构。